Late start of COVID treatment may still benefit immunocompromised patients, study finds
Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, who are at greatest risk of developing severe COVID-19, according to researchers.